Chen R (2015), Biology of Blood and Marrow Transplantation (Link to abstract)
Brentuximab vendolin (BV, anti CD30 antibody conjugated to monomethyl auristatin E) is currently used in Hodgkin Lymphoma (HL) patients as a third-line treatment usually to bridge to autologous hematopoietic stem cell transplantation (HSCT). In this multicenter prospective phase II trial the activity and toxicity of BV were examined for relapsed/ refractory HL as a second-line treatment, bridging for autologous HSCT. Of 37 patients, the overall response rate was 68%, and the drug was well tolerated, with 32 (86%) of the patients proceeding to autologous HSCT.
* This study demonstrated that brentuximab vedotin as second-line therapy for patients with HL is active, well tolerated, and does not hinder stem cell collection or engraftment.